Clinical Trial

Chinese Adults With Kidney Disease

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a Phase 2 study to assess the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics of ADX-038 in adults with complement-mediated kidney diseases. The study will enroll Chinese adults with IgA nephropathy, complement 3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study will evaluate ADX-038 administered alone (Part A) and in combination with telitacicept (Part B).
Protocol Amendment History 4 changes
notable Trial sites expanded: 5 -> 10 locations 2026-04-23
critical Recruitment opened 2026-04-15
notable Trial sites expanded: 0 -> 5 locations 2026-04-15
minor Completion pushed: 2028-07-10 -> 2029-01-21 2026-04-15
Trial Details
NCT Number NCT07522099
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
Enrollment 30 participants
Start Date 2026-05-21
Primary Completion 2028-07-10 (estimated)
Study Completion 2029-01-21 (estimated)
Updated on ClinicalTrials.gov 2026-07-27